Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy

Ninety-eight patients with pathological Stage (PS) III Hodgkin's disease treated between 1969 and 1984 were retrospectively analyzed. Treatment consisted of radiation therapy (RT) alone in 46 patients and combined radiation therapy and chemotherapy (CMT) in 52 patients. The median follow-up was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of radiation oncology, biology, physics biology, physics, 1989-10, Vol.17 (4), p.761-766
Hauptverfasser: Farah, Ramez, Golomb, Harvey M., Hallahan, Dennis E., Desser, Richard K., Griem, Melvin L., Blough, Richard, Ultmann, John E., Weichselbaum, Ralph R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Ninety-eight patients with pathological Stage (PS) III Hodgkin's disease treated between 1969 and 1984 were retrospectively analyzed. Treatment consisted of radiation therapy (RT) alone in 46 patients and combined radiation therapy and chemotherapy (CMT) in 52 patients. The median follow-up was 10 years (range 3–19 years). Fifteen-year survival for patients with Stage III 1 is better than for Stage III 2 patients (82% vs 53%; p = .014). Patients with Stage III 1A have a favorable prognosis regardless of treatment modality. The probability of freedom from relapse at 15 years for patients with pathological Stage III 1A treated with radiation therapy is 70%, compared to 83% for pathological Stage III 1A patients treated with combined modality therapy ( p = .56). In patients with pathological Stage III 2A, III 1B, and III 2B relapses were less frequent with the use of combined modality therapy compared to radiation therapy. We conclude that pathological Stage III 1A patients may be treated with radiation therapy alone; the other subsets of patients benefit from combined radiation and chemotherapy.
ISSN:0360-3016
1879-355X
DOI:10.1016/0360-3016(89)90063-1